Conolidine’s analgesic consequences stem from its interaction with non-opioid pain pathways. Not like opioids, which bind to µ-opioid receptors within the central anxious process, conolidine modulates alternate molecular targets. A Science Advancements review found that conolidine interacts Along with the atypical chemokine receptor ACKR3/CXCR7, which regulates opioid peptide availabi... https://lechu097svw8.vidublog.com/profile